As shown in Figure A2 and Figure A3, the incidence of CRS in either ≥ grade 3 or any grade was significantly decreased in alternative CD19-CAR-T treatment compared with the traditional second generation CD19 CAR-T therapy. This evidence concerns the gene CD19 and congenital rubella syndrome.